Study of Estrogen Sulfotransferase and Steroid Sulfatase in Breast Cancer
Author Information
Author(s): Poisson Paré D., Song D., Luu-The V., Han B., Li S., Liu G., Labrie F., Pelletier G.
Primary Institution: Laval University Hospital Research Center
Hypothesis
The combined action of steroid sulfatase (STS) and estrogen sulfotransferase (EST1E1) affects the development of hormone-dependent breast cancer.
Conclusion
The study found that STS is overexpressed in breast cancer and associated with a worse prognosis, while EST1E1 was positively correlated with better prognostic factors.
Supporting Evidence
- STS expression was higher in carcinoma specimens than in adjacent normal tissues.
- EST1E1 was observed for the first time in the nuclei of epithelial and tumoral cells.
- Controlling STS overexpression could inhibit cancer growth.
Takeaway
This study looked at two important enzymes in breast cancer and found that one is linked to worse outcomes while the other might help protect against cancer.
Methodology
The expression of STS and EST1E1 was studied in 88 breast carcinomas and 57 adjacent non-malignant tissues using immunohistochemistry.
Limitations
Menopausal status was unknown for most patients, and the study did not measure tumor size or risk of recurrence for many cases.
Participant Demographics
Mean age of participants was 50.9 years, with a range from 32 to 73 years.
Statistical Information
P-Value
p = 0.064 for STS expression comparison
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website